

Giuseppe Lo Russo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8724269/publications.pdf>

Version: 2024-02-01

106
papers

2,444
citations

186265

28
h-index

233421

45
g-index

107
all docs

107
docs citations

107
times ranked

4516
citing authors

#	ARTICLE	IF	CITATIONS
1	Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy. <i>Cancers</i> , 2022, 14, 435.	3.7	14
2	Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. <i>Future Oncology</i> , 2022, 18, 2593-2604.	2.4	3
3	Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. <i>Clinical Lung Cancer</i> , 2021, 22, e180-e192.	2.6	15
4	Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. <i>ESMO Open</i> , 2021, 6, 100034.	4.5	0
5	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. <i>Lung Cancer</i> , 2021, 152, 165-173.	2.0	23
6	Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. <i>Cancers</i> , 2021, 13, 1300.	3.7	10
7	Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103299.	4.4	5
8	The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021, 6, 100078.	4.5	35
9	A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer. <i>Molecular Therapy</i> , 2021, 29, 2963-2978.	8.2	9
10	Recent Advances in the Management of Typical and Atypical Lung Carcinoids. <i>Clinical Lung Cancer</i> , 2021, 22, 161-169.	2.6	17
11	Pozotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. <i>European Journal of Cancer</i> , 2021, 149, 235-248.	2.8	46
12	Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. <i>Translational Lung Cancer Research</i> , 2021, 10, 2955-2969.	2.8	2
13	Immune-checkpoint inhibitors in advanced non-small cell lung cancer with uncommon histology. <i>Clinical Lung Cancer</i> , 2021, , .	2.6	10
14	Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2020, 12, 67.	3.7	39
15	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy. <i>JCO Precision Oncology</i> , 2020, 4, 829-840.	3.0	25
16	ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?. <i>Thrombosis Research</i> , 2020, 194, 176-177.	1.7	5
17	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. <i>Translational Lung Cancer Research</i> , 2020, 9, 617-628.	2.8	8
18	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , 2020, 150, 123-131.	2.0	13

#	ARTICLE	IF	CITATIONS
19	LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. ESMO Open, 2020, 5, e000748.	4.5	2
20	Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study. Thoracic Cancer, 2020, 11, 1661-1669.	1.9	1
21	Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score $\geq 50\%$ treated with front-line pembrolizumab. Acta Oncologica, 2020, 59, 1058-1063.	1.8	31
22	DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. Clinical Lung Cancer, 2020, 21, e337-e348.	2.6	6
23	Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. Lung Cancer, 2020, 142, 70-79.	2.0	17
24	Recurrent thrombosis followed by Lazarus response in <i>ROS1</i> rearranged NSCLC treated with crizotinib: a case report. Tumori, 2020, 106, NP41-NP45.	1.1	3
25	Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?. Oncologist, 2020, 25, 94-98.	3.7	58
26	Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer. Current Oncology Reports, 2020, 22, 41.	4.0	20
27	Is hyperprogressive disease a specific phenomenon of immunotherapy?. Exploration of Targeted Anti-tumor Therapy, 2020, 1, .	0.8	1
28	Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy. European Oncology and Haematology, 2020, 16, 39.	0.0	0
29	mutations confer poor prognosis in malignant pleural mesothelioma. Translational Lung Cancer Research, 2020, 9, 1940-1951.	2.8	0
30	SMO mutations confer poor prognosis in malignant pleural mesothelioma. Translational Lung Cancer Research, 2020, 9, 1940-1951.	2.8	4
31	Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs. Future Oncology, 2019, 15, 3015-3024.	2.4	3
32	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. Future Oncology, 2019, 15, 2743-2757.	2.4	7
33	The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. Clinical Lung Cancer, 2019, 20, e652-e660.	2.6	6
34	Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987772.	3.2	16
35	Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer. Tumori, 2019, 105, NP57-NP62.	1.1	7
36	Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer, 2019, 137, 38-42.	2.0	44

#	ARTICLE	IF	CITATIONS
37	Combined surgery and radiotherapy as curative treatment for tracheal adenoid cystic carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 52.	0.8	10
38	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 72-78.	2.0	54
39	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019, 4, e000457.	4.5	151
40	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. <i>Cancer Treatment Reviews</i> , 2019, 75, 39-51.	7.7	124
41	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. <i>Lung Cancer</i> , 2019, 132, 17-23.	2.0	12
42	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. <i>Oncologist</i> , 2019, 24, e1165-e1171.	3.7	35
43	How to recognize and manage hyper-progression and pseudo- progression during immune checkpoint blockade in non-small cell lung cancer. <i>Precision Cancer Medicine</i> , 2019, 2, 35-35.	1.8	3
44	EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. <i>Cancers</i> , 2019, 11, 1954.	3.7	57
45	Antibodyâ€“Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Nonâ€“small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 989-999.	7.0	315
46	Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. <i>Clinical Cancer Research</i> , 2019, 25, 2166-2173.	7.0	67
47	Immune-checkpoints inhibitors in metastatic non small cell lung cancer with rare histology.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9106-9106.	1.6	4
48	Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 â‰¥50% who progress on first-line immunotherapy: real-world data from a European cohort. <i>Journal of Thoracic Disease</i> , 2019, 11, 4972-4981.	1.4	35
49	Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 353-361.	2.4	3
50	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	1.3	54
51	The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. <i>Tumori</i> , 2018, 104, 88-95.	1.1	17
52	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 607-618.	3.1	18
53	MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review. <i>Frontiers in Oncology</i> , 2018, 8, 650.	2.8	40
54	Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. <i>Tumor Biology</i> , 2018, 40, 101042831881504.	1.8	6

#	ARTICLE	IF	CITATIONS
55	Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. <i>Targeted Oncology</i> , 2018, 13, 795-800.	3.6	15
56	Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1146-1155.	1.1	77
57	Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. <i>Lung Cancer</i> , 2018, 115, 135-142.	2.0	27
58	Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. <i>Future Oncology</i> , 2017, 13, 1677-1683.	2.4	5
59	Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 183-188.	3.2	20
60	Cognitive impairment and chemotherapy: a brief overview. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 118, 7-14.	4.4	55
61	FNA and CNB in the Diagnosis of Pulmonary Lesions: A Single-center Experience on 665 Patients, Comparison between Two Periods. <i>Tumori</i> , 2017, 103, 360-366.	1.1	5
62	Treatment in EGFR-mutated Non-small Cell Lung Cancer: How to Block the Receptor and overcome Resistance Mechanisms. <i>Tumori</i> , 2017, 103, 325-337.	1.1	12
63	Concomitant <i>EML4-ALK</i> rearrangement and <i>EGFR</i> mutation in non-small cell lung cancer patients: a literature review of 100 cases. <i>Oncotarget</i> , 2017, 8, 59889-59900.	1.8	33
64	Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem. <i>Current Drug Targets</i> , 2017, 18, 341-362.	2.1	8
65	Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities A Case Report with a 6-Year Follow-Up. <i>Case Reports in Oncology</i> , 2016, 9, 432-439.	0.7	4
66	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. <i>Translational Lung Cancer Research</i> , 2016, 5, 563-578.	2.8	30
67	Safety of Lanreotide 120 mg ATG in combination with metformin in patients with progressive advanced well-differentiated gastro-intestinal (GI) or lung carcinoids. A pilot, one-arm, open-label, prospective study: the MetNET-2 trial. <i>Annals of Oncology</i> , 2016, 27, iv25.	1.2	0
68	Impact of Hyponatremia in a Tertiary Cancer Center: a one-year-Survey at National Cancer Institute of Milan. <i>Annals of Oncology</i> , 2016, 27, iv112.	1.2	0
69	Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging. <i>Annals of Oncology</i> , 2016, 27, iv13.	1.2	0
70	Diagnosis and management of typical and atypical lung carcinoids. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 167-176.	4.4	35
71	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2016, 18, 59.	4.0	35
72	Update on medical treatment of small intestinal neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 969-976.	2.4	4

#	ARTICLE	IF	CITATIONS
73	Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. <i>Tumor Biology</i> , 2016, 37, 12991-13003.	1.8	16
74	Current Status of Immunotherapy for Non-Small-Cell Lung Cancer. <i>Tumori</i> , 2016, 102, 337-351.	1.1	6
75	Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?. <i>Tumori</i> , 2016, 102, 18-30.	1.1	8
76	Is the Chemotherapy Era in Advanced Non-Small Cell Lung Cancer Really Over? Maybe not Yet. <i>Tumori</i> , 2016, 102, 223-225.	1.1	7
77	Impact of hyponatremia in a tertiary cancer center: a one-year-survey at National Cancer Institute of Milan. <i>Annals of Oncology</i> , 2016, 27, vi509.	1.2	1
78	Complete response to avelumab in Merkel Cell Carcinoma, and potential correlation with toxicity: a case report. <i>Annals of Oncology</i> , 2016, 27, iv119.	1.2	1
79	Safety of lanreotide 120 mg ATC in combination with metformin in patients with advanced well-differentiated gastro-intestinal (GI) or lung carcinoids. A pilot, one-arm, open-label, prospective study: The MetNET-2 trial. <i>Annals of Oncology</i> , 2016, 27, vi148.	1.2	0
80	209P: SMO mutation is a strong negative prognostic factor in malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, S147.	1.1	0
81	Treatment of lung large cell neuroendocrine carcinoma. <i>Tumor Biology</i> , 2016, 37, 7047-7057.	1.8	46
82	How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. <i>Oncotarget</i> , 2016, 7, 44841-44847.	1.8	15
83	Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?. <i>Translational Lung Cancer Research</i> , 2016, 5, 110-4.	2.8	9
84	Investigating Molecular Profiles of Ovarian Cancer: An Update on Cancer Stem Cells. <i>Journal of Cancer</i> , 2014, 5, 301-310.	2.5	39
85	Clinical use of fertility agents and risk of breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2014, 26, 130-137.	2.0	3
86	Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. <i>Tumor Biology</i> , 2014, 35, 6195-6206.	1.8	91
87	Fertility drugs, reproductive strategies and ovarian cancer risk. <i>Journal of Ovarian Research</i> , 2014, 7, 51.	3.0	23
88	Correlation between fertility drugs use and malignant melanoma incidence: the state of the art. <i>Tumor Biology</i> , 2014, 35, 8415-8424.	1.8	10
89	Single-center experience with pegfilgrastim (P) and lenograstim (L) in nonmetastatic breast cancer (NMBC) patients (pts) during adjuvant FEC100 or sequential FEC100 plus DOCETAXEL100 (D100).. <i>Journal of Clinical Oncology</i> , 2014, 32, e12005-e12005.	1.6	1
90	G-CSF related bone pain (BP) and Bv8/PK2 expression: Is there a link in breast cancer (BC) patients (pts) treated with FEC100 adjuvant chemotherapy (CT)?. <i>Journal of Clinical Oncology</i> , 2014, 32, e20672-e20672.	1.6	1

#	ARTICLE	IF	CITATIONS
91	The role of BMI and age in chemotherapy-induced amenorrhea (CIA) in premenopausal breast cancer (PBC) patients treated with adjuvant FEC100 with or without docetaxel (D).. Journal of Clinical Oncology, 2014, 32, e12000-e12000.	1.6	1
92	A 68-year-old Caucasian man presenting with urinary bladder lymphoepithelioma: a case report. Journal of Medical Case Reports, 2013, 7, 161.	0.8	6
93	Circulating tumor cells in high-risk nonmetastatic colorectal cancer. Tumor Biology, 2013, 34, 2507-2509.	1.8	40
94	Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1411-1416.	2.5	30
95	Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. Journal of Experimental and Clinical Cancer Research, 2013, 32, 48.	8.6	72
96	Breast cancer risk after exposure to fertility drugs. Expert Review of Anticancer Therapy, 2013, 13, 149-157.	2.4	11
97	Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). Cancer Management and Research, 2013, 5, 377.	1.9	10
98	Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. Therapeutics and Clinical Risk Management, 2013, 9, 457.	2.0	12
99	Chemotherapy and Target Therapy in the Management of Adult High- Grade Gliomas. Current Cancer Drug Targets, 2012, 12, 1016-1031.	1.6	19
100	Emerging Role of Cetuximab in the Treatment of Colorectal Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2012, 7, 233-247.	1.6	9
101	Breast cancer metastatic to the pituitary gland: a case report. World Journal of Surgical Oncology, 2012, 10, 137.	1.9	29
102	Subcutaneous metastases from colon cancer: a case report. Journal of Medical Case Reports, 2012, 6, 212.	0.8	7
103	“Long extended” temozolomide in a selected population with not radically resected high-grade gliomas.. Journal of Clinical Oncology, 2012, 30, e12510-e12510.	1.6	0
104	Is CEA Better than CYFRA 21-1 in the Monitoring of Squamous Cell Lung Cancer Progression?. Medical Principles and Practice, 2011, 20, 200-200.	2.4	1
105	Cysts of the canal of Nuck: ultrasound and magnetic resonance imaging findings. Journal of Ultrasound, 2009, 12, 125-127.	1.3	36
106	Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation. Frontiers in Oncology, 0, 12, .	2.8	6